Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Naturally Aged Tetravalent Dengue Vaccine (TDV) in Healthy Adults
NCT03771963Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dengue tetravalent vaccine (live, attenuated) in dengue fever, sponsored by Takeda. Started Mar 2019; status: completed.
02
Drugs
dengue tetravalent vaccine (live, attenuated)
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03771963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771963.